225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy - an in vitro and in vivo evaluation

被引：0
|
作者：
Rodak, Magdalena [1 ]
Dekempeneer, Yana [2 ]
Wojewodzka, Maria [1 ]
Lahoutte, Tony [3 ]
Bruchertseifer, Frank [4 ]
Morgenstern, Alfred [4 ]
D'Huyvetter, Matthias [3 ]
Pruszynski, Marek [1 ]
机构：
[1] Inst Nucl Chem & Technol, Warsaw, Poland
[2] Nucl Res Ctr, Brussels, Belgium
[3] Vrije Univ Brussel, Brussels, Belgium
[4] Inst Transuranium Elements, Karlsruhe, Germany
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2021年 / 96-97卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
SSP-30
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 35 条
  • [21] A novel alpha particle emitting 225Ac labeled anti-CD33 antibody construct:: Synthesis and in vitro evaluation of biochemistry, potency, specificity and mechanism of cell death.
    McDevitt, MR
    Miederer, M
    Ma, D
    Curcio, MJ
    Lai, LT
    Pellegrini, V
    Brechbiel, MW
    Scheinberg, DA
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 30P - 30P
  • [22] ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy
    McAfee, John L.
    Hoda, Raza S.
    Hoyle, Carrie
    McCoy, Lauren
    Sprague, Cathy
    Reddy, Chandana A.
    Koyfman, Shlomo A.
    Geiger, Jessica L.
    Komforti, Miglena K.
    Griffith, Christopher C.
    MODERN PATHOLOGY, 2023, 36 (10)
  • [23] Preclinical evaluation of targeted alpha therapy using 225Ac-DOTA-E[c(RGDfK)]2 for pancreatic cancer
    Yoshimoto, M.
    Washiyama, K.
    Yoshii, Y.
    Ohnuki, K.
    Fujii, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S650 - S650
  • [24] Evaluation of targeted alpha therapy using 225Ac-DOTA-E[c(RGDfK)]2 in PDCA mice model
    Yoshimoto, Mitsuyoshi
    Washiyama, Kohshin
    Ohnuki, Kazunobu
    Kojima, Motohiro
    Miller, Brian W.
    Yoshii, Yukie
    Fujii, Hirofumi
    Inaki, Anri
    CANCER SCIENCE, 2025, 116 : 1821 - 1821
  • [25] In vivo evaluation of site-specifically labelled ABD-fused anti-HER2 Affibody molecule for radionuclide therapy
    Orlova, A.
    Ekblad, C.
    Abrahmsen, L.
    Wennborg, A.
    Frejd, F. Y.
    Tolmachev, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S232 - S232
  • [26] Pre-clinical evaluation of 225Ac-DOTAE[c(RGDfK)]2 for targeted alpha therapy in PDCA mice model
    Yoshimoto, Mitsuyoshi
    Washiyama, Kohshin
    Ohnuki, Kazunobu
    Kojima, Motohiro
    Miller, Brian
    Yoshii, Yukie
    Fujii, Hirohumi
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [27] Optimizing the therapeutic index of targeted α -particle radioimmuotherapy (TART) of HER2-positive breast cancer tumors in NRG mice with 225Ac-labeled trastuzumab
    Kondo, Misaki
    Cai, Zhongli
    Chan, Conrad
    Reilly, Raymond M.
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Improved efficacy of α-emitters (225Ac, 213Bi) over β-emitter (90Y) labeled anti-HER-2/neu monoclonal antibody against early stage pulmonary metastasis
    Song, H.
    Esaias, C.
    Vajravelu, R.
    Hobbs, R. F.
    Apostolidis, C.
    Morgenstern, A.
    Sgouros, G.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 519 - 519
  • [29] GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy
    Tian, Chunyu
    Zhang, Hongxu
    Liu, Jianping
    Xu, Mengze
    Ma, Lihui
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [30] [225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts
    Misaki Kondo
    Zhongli Cai
    Conrad Chan
    Nubaira Forkan
    Raymond M. Reilly
    EJNMMI Radiopharmacy and Chemistry, 8
1234